Cancer News and Research

Latest Cancer News and Research

First international molecular screening program at IMPAKT for metastatic breast cancer

While research has made great strides in recent decades to improve and significantly extend the lives of patients with early breast cancer, the needs of patients with advanced or metastatic disease have largely been ignored.

8 May 2014

Regular doctor visits may reduce melanoma mortality, says study

The risk of dying from the most dangerous type of skin cancer is significantly reduced with regular doctor visits, according to a Henry Ford Hospital study.

8 May 2014

Scientists find 2 key proteins that regulate growth of mammary stem cells and contribute to breast cancer

By carefully controlling the levels of two proteins, researchers at the Salk Institute have discovered how to keep mammary stem cells-those that can form breast tissue-alive and functioning in the lab. The new ability to propagate mammary stem cells is allowing them to study both breast development and the formation of breast cancers.

8 May 2014

Researchers create universal flu vaccine

Researchers at the University of Texas Medical Branch are working to create a universal flu vaccine - one that could eliminate the need for an annual flu shot.

8 May 2014

Bioengineers develop tool that reacts to chemical changes caused by cancer cells

Bioengineers at the University of Rome Tor Vergata and the University of Montreal have used DNA to develop a tool that detects and reacts to chemical changes caused by cancer cells and that may one day be used to deliver drugs to tumor cells.

8 May 2014

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD Pharmaceuticals, Inc. today reported financial results for the first quarter of 2014, including revenue from sales of Iclusig® (ponatinib) and licensing agreements. The Company also provided an update on corporate developments.

7 May 2014

Molecular subtyping provides insights into how to treat breast cancer

New evidence showing that the MammaPrint® and BluePrint® tests provide insights into how to treat breast cancer was presented at the annual conference of the American Society of Breast Surgeons (ASBrS).

7 May 2014

ArQule reports net loss of $7,141,000 in first quarter 2014

ArQule, Inc. today announced its financial results for the first quarter of 2014. For the quarter ended March 31, 2014, the Company reported a net loss of $7,141,000 or $0.11 per share, compared to a net loss of $5,775,000, or $0.09 per share, for the first quarter of 2013.

7 May 2014

Perfusion system at room temperature preserves and improves metabolic function of donor livers

A system developed by investigators at the Massachusetts General Hospital (MGH) Center for Engineering in Medicine (CEM) and the MGH Transplant Center has the potential to increase both the supply and the quality of donor organs for liver transplantation.

7 May 2014

Johns Hopkins to use $65 million gift to expand Sidney Kimmel Comprehensive Cancer Center

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins will use a $65 million gift toward the construction of a new patient care building that will be named for the late Albert P. “Skip” Viragh, Jr., a Maryland mutual fund investment leader and philanthropist.

7 May 2014

First Edition: May 7, 2014

Today's headlines include a story noting that insurers say about 80 percent of new enrollees have paid their first premiums for new insurance coverage under the health law.

7 May 2014

Virginia Senate Democrats want GOP counterparts to offer Medicaid expansion alternatives

The state's Democratic legislators called on GOP lawmakers to present an alternative proposal -- one that was promised, they say, months ago to close the so-called coverage gap.

7 May 2014

TGen/George Mason create strategic research alliance to benefit patients with cancer, life-threatening illnesses

The Translational Genomics Research Institute (TGen) and George Mason University today announced the creation of a strategic research alliance to benefit patients with cancer and other life-threatening illnesses.

7 May 2014

RPCI research finds patients with metastatic kidney cancer benefit from HDIL-2 immunotherapy

A retrospective study published online ahead of print in the medical journal Urology by a physician team from Roswell Park Cancer Institute (RPCI) found that patients with metastatic kidney cancer — even those with chronic renal insufficiency — can tolerate and benefit from a treatment called high-dose interleukin-2 (HDIL-2) immunotherapy.

7 May 2014

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1

7 May 2014

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Exelixis, Inc. today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

7 May 2014

NanoString receives license from Health Canada to market Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that it has received a Class III Medical Device License from Health Canada, clearing the company to market its Prosigna Breast Cancer Prognostic Gene Signature Assay for assessing a woman's 10-year risk of distant recurrence and accurately identifying the intrinsic biologic subtype of the tumor.

From NanoString Technologies 7 May 2014

Cancer News and Research

Latest Cancer News and Research

First international molecular screening program at IMPAKT for metastatic breast cancer

Regular doctor visits may reduce melanoma mortality, says study

Scientists find 2 key proteins that regulate growth of mammary stem cells and contribute to breast cancer

Researchers create universal flu vaccine

Bioengineers develop tool that reacts to chemical changes caused by cancer cells

ARIAD provides update on corporate developments, reports Q1 2014 financial results

Molecular subtyping provides insights into how to treat breast cancer

ArQule reports net loss of $7,141,000 in first quarter 2014

Perfusion system at room temperature preserves and improves metabolic function of donor livers

Johns Hopkins to use $65 million gift to expand Sidney Kimmel Comprehensive Cancer Center

First Edition: May 7, 2014

Virginia Senate Democrats want GOP counterparts to offer Medicaid expansion alternatives

TGen/George Mason create strategic research alliance to benefit patients with cancer, life-threatening illnesses

RPCI research finds patients with metastatic kidney cancer benefit from HDIL-2 immunotherapy

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

NanoString receives license from Health Canada to market Prosigna Breast Cancer Prognostic Gene Signature Assay

New molecular "clamps" offer powerful new tool for identifying individuals with increased risk of cancer

Rice University researchers find new possibilities for benign, 'tunable' virus

Environmental researchers call for ban on cigarette filters

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in